TRT therapy is delivered as topical gels, transdermal patches, intramuscular injections, or subcutaneous pellets. For clinicians, the decision to treat rests on both lab values and a clear symptom profile, not on a single test or an age-based assumption. Men whose morning blood tests show consistently low testosterone, accompanied by symptoms. The strongest evidence supports Testosterone Replacement Therapy for men with confirmed hypogonadism. This evidence, together with the beneficial effects of testosterone replacement on central obesity and diabetes, raises the question whether testosterone treatment could be beneficial in preventing or treating atherosclerosis. Concerns about the potential adverse effects of testosterone treatment on cardiovascular disease have previously contributed to caution in prescribing testosterone to those who have, or who are at risk of, cardiovascular disease. This results in reduced testosterone levels, which increase the action of lipoprotein lipase and increase fat mass, thus increasing aromatisation of testosterone and completing the cycle. Baseline testosterone levels were in the low-normal range and patients received a relatively small dose of 100 mg intramuscular testosterone every three weeks. The epidemiological and experimental data propose a potential role of testosterone in protecting cognitive function and preventing Alzheimer’s disease. Reviewing different cognitive strengths of male versus female humans is not within the scope of this article but the idea that cognition could be altered by testosterone deserves attention. Many would now suggest screening for testosterone deficiency in all men presenting with erectile dysfunction (Gore and Rajfer 2004; Shabsigh 2005). The symptoms of aging include tiredness, lack of energy, reduced strength, frailty, loss of libido, decreased sexual performance depression and mood change. The options available for treatment have increased in recent years with the availability of a number of testosterone preparations which can reliably produce physiological serum concentrations. Further controversy surrounds setting a lower limit of normal testosterone, the limitations of the commonly available total testosterone result in assessing some patients and the unavailability of reliable measures of bioavailable or free testosterone for general clinical use. An international consensus document was recently published and provides guidance on the diagnosis, treatment and monitoring of late-onset hypogonadism (LOH) in men. Science doesn’t support the idea that TRT extends life or significantly improves age-related decline in otherwise healthy men. Simultaneously, the body experiences thymic involution, where the thymus gland, the primary organ responsible for maturing immune T-cells, begins to shrink. The most impactful change is somatopause, the natural and progressive decline in growth hormone (GH) production. The human body is governed by signaling molecules, and many of the most important ones begin a measurable decline in our 30s, becoming clinically significant by our 40s and 50s. This guide breaks down exactly which peptides are being used, why they work synergistically, and how to approach them intelligently. Modern anti-aging peptide research has uncovered ways to address these declines at the molecular level. Some studies have linked testosterone therapy to an increased risk of heart attacks, strokes, and blood clots, especially in older men or those with pre-existing heart conditions. Some studies have found that TRT can increase lean body mass slightly, but it doesn’t always improve strength or endurance. Some biohackers even inject testosterone not because they have low levels, but because they want to "optimize" their hormones. Some men, however, experience a more rapid or significant decline in testosterone levels. Just a more complete way of looking at health. We also believe patients deserve honesty. We do not use the term longevity medicine because it sounds trendy to us. And that is exactly why language matters. They want to stay active, attractive, capable, independent, and engaged in their own lives for as long as possible. Aggression should therefore be monitored but in our experience is rarely a significant problem during testosterone replacement producing physiological levels. An increase in self-reported aggressive behaviors have also been reported in one double blind placebo controlled trial of testosterone in young hypogonadal men (Finkelstein et al 1997), but this has not been confirmed in other studies (Skakkebaek et al 1981; O’Connor et al 2002). On the other hand, late onset hypogonadism frequently results in anemia which will then normalize during physiological testosterone replacement. The absence of such data leads us to examine the relationship of testosterone to other cardiovascular risk factors, such as adverse lipid parameters, blood pressure, endothelial dysfunction, coagulation factors, inflammatory markers and cytokines. No trial of sufficient size or duration has investigated the effect of testosterone replacement in primary or secondary prevention cardiovascular disease. A 4-year follow up study of the latter population showed that free testosterone was also inversely correlated with the rate of increase of IMT (Muller et al 2004).
